{"id":44214,"date":"2025-10-23T20:37:54","date_gmt":"2025-10-23T12:37:54","guid":{"rendered":"https:\/\/flcube.com\/?p=44214"},"modified":"2025-10-23T20:37:54","modified_gmt":"2025-10-23T12:37:54","slug":"boehringer-ingelheims-nerandomilast-approved-by-china-nmpa-for-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44214","title":{"rendered":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis"},"content":{"rendered":"\n<p>Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor <strong>Nerandomilast (JASCAYD\u00ae)<\/strong> has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Nerandomilast (JASCAYD\u00ae) \u2013 oral PDE4B inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult IPF (United States) and IPF in China<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA approval (China) \u2013 Priority Review &amp; Approval Procedure<\/td><\/tr><tr><td><strong>US Status<\/strong><\/td><td>FDA Breakthrough Therapy Designation (Feb\u202f2022) &amp; approval (Oct\u202f2025)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective PDE4B blockade \u2192 dual anti\u2011fibrotic &amp; immunomodulatory effects<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-impact\"><strong>Clinical Impact<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fIII Success<\/strong>: Nerandomilast met its primary endpoint in a pivotal study, demonstrating significant slowing of disease progression and improvement in lung function.<\/li>\n\n\n\n<li><strong>Dual\u2011Action Profile<\/strong>: By selectively inhibiting the lung\u2011enriched PDE4B isoenzyme, the drug dampens both fibrotic signalling and inflammatory cascades.<\/li>\n\n\n\n<li><strong>Patient\u2011Centric Benefits<\/strong>: Oral administration enhances adherence and reduces hospital visits compared with inhaled or intravenous therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-significance\"><strong>Regulatory Significance<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First New IPF Therapy in 10\u202fYears<\/strong>: The approval ends a decade\u2011long stagnation in IPF drug development.<\/li>\n\n\n\n<li><strong>Priority Review<\/strong>: NMPA\u2019s expedited pathway underscores the unmet need and robust evidence base for Nerandomilast.<\/li>\n\n\n\n<li><strong>Global Harmonization<\/strong>: The simultaneous US and Chinese approvals position Nerandomilast for rapid adoption across key markets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-commercial-outlook\"><strong>Market &amp; Commercial Outlook<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing &amp; Reimbursement<\/strong>: Boehringer Ingelheim is working with Chinese payers to secure favorable reimbursement terms, leveraging the drug\u2019s breakthrough status.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong>: The company plans to expand its distribution network in Asia\u2011Pacific and Europe, supported by robust pharmacovigilance data.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong>: Nerandomilast\u2019s success fuels Boehringer\u2019s broader anti\u2011fibrotic platform, including agents for progressive pulmonary fibrosis (PPF).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44215,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[390,71,15,24],"class_list":["post-44214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boehringer-ingelheim","tag-nmpa-fda-filing","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44214\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44214\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-23T12:37:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis\",\"datePublished\":\"2025-10-23T12:37:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2307.webp\",\"keywords\":[\"Boehringer Ingelheim\",\"NMPA &amp; FDA Filing\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44214#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44214\",\"name\":\"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2307.webp\",\"datePublished\":\"2025-10-23T12:37:54+00:00\",\"description\":\"Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44214\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2307.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44214#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44214","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis","og_description":"Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.","og_url":"https:\/\/flcube.com\/?p=44214","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-23T12:37:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44214#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44214"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis","datePublished":"2025-10-23T12:37:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44214"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44214#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp","keywords":["Boehringer Ingelheim","NMPA &amp; FDA Filing","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44214#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44214","url":"https:\/\/flcube.com\/?p=44214","name":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44214#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44214#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp","datePublished":"2025-10-23T12:37:54+00:00","description":"Boehringer Ingelheim announced that its oral selective phosphodiesterase\u20114B (PDE4B) inhibitor Nerandomilast (JASCAYD\u00ae) has received formal approval from the China National Medical Products Administration (NMPA) for the treatment of adult Idiopathic Pulmonary Fibrosis (IPF). The approval marks the first IPF drug to hit a Phase\u202fIII primary endpoint and secure regulatory clearance in more than a decade, breaking a longstanding treatment void.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44214#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44214"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44214#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44214#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim\u2019s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44214"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44214\/revisions"}],"predecessor-version":[{"id":44216,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44214\/revisions\/44216"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44215"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}